Showing results (91-100 of 374) with videos related to

Sort By:
Pageof 38
Diabetes Care|February 24, 2018
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 DiabetesCharlotte Koopal, Frank L J Visseren, Jan Westerink, et al.
European Journal of Preventive Cardiology|July 28, 2017
SPRINT trial: It's not just the blood pressure!Gijs Fn Berkelmans, Frank Lj Visseren, Nicole Em Jaspers, et al.
The American Journal of Cardiology|January 3, 2015
Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular diseaseAnton P van de Woestijne, Yolanda van der Graaf, Jan Westerink, et al.
Cardiovascular Diabetology|October 18, 2017
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trialsMarit de Jong, H Bart van der Worp, Yolanda van der Graaf, et al.
Plos One|April 27, 2012
Unrequested findings on cardiac computed tomography: looking beyond the heartConstantinus F Buckens, Helena M Verkooijen, Martijn J Gondrie, et al.
Cardiovascular Diabetology|November 22, 2011
Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART studySandra N Verhagen, Annemarie M J Wassink, Yolanda van der Graaf, et al.
European Journal of Clinical Investigation|February 13, 2013
Hepatocyte growth factor and interferon-γ inducible protein-10 are related to visceral adiposityDaniël R Faber, Yolanda van der Graaf, Jan Westerink, et al.
Pageof 38